Trial Profile
A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Patients With Resectable Gastric and Gastroesophageal Junction Cancer (GC/GEJC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Apr 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Docetaxel; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Registrational; Therapeutic Use
- Acronyms MATTERHORN
- Sponsors AstraZeneca; AstraZeneca AB
- 20 Jan 2024 Results of sub-group analysis by region assessing complete response rates with FLOT and benefit of D + FLOT across the global study population, presented at the 2024 Gastrointestinal Cancers Symposium.
- 24 Oct 2023 Results of pre-planned interim analysis assessing pathological complete response (pCR) were presented at the 48th European Society for Medical Oncology Congress.
- 20 Oct 2023 According to an AstraZeneca media release, trial will continue to assess primary endpoint of event-free survival.